Jefferies Downgrades Teva Pharmaceutical Industries Limited (TEVA) to Hold with no specific Price Target. Drug Data Sends Paratek Pharmaceuticals Stock Soaring After closing Monday at $18.60, PRTK stock has surged 30% in pre-market trading, on track for a multi-year high.
Other equities research analysts have also issued reports about the stock. Argus Research maintained the shares of TEVA in report on Tuesday, July 28 with "Buy" rating.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) yearly performance is -39.21% and net profit margin is 0.30%.
01/31/2017 - Teva Pharmaceutical Industries Limited had its "outperform" rating reiterated by analysts at Oppenheimer.
Analysts give DISH a mean recommendation of 2.50.
The current consensus rating on Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is Hold (Score: 2.48) with a consensus target price of $45.59 per share, a potential 42.77% upside. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock.
The company said on Monday that the FDA approval was based on results from a late-stage study of the drug, Austedo, in reducing chorea in patients with Huntington's disease.
Teva Pharmaceutical Industries Limited now measures the Current ratio at 0.9 and displays the quick ratio at 0.6.
The company's price sits -4.50% below from its 50-day moving average of $34.07 and -23.27% below from the stock's 200-day moving average which is $38.17. Kistler Tiffany Companies LLC increased its stake in Teva Pharmaceutical Industries by 14.1% in the third quarter. According to these analysts, the Low Revenue Estimate for Teva Pharmaceutical Industries Limited is 5.14 Billion and the High Revenue Estimate is 6.07 Billion.
On 11/15/2016 Teva Pharmaceutical Industries Ltd announced a quarterly dividend of $0.34 with an ex dividend date of 12/1/2016 which will be payable on 12/20/2016. Looking at this figure it suggests that the shares of Teva Pharmaceutical Industries Limited (TEVA) may be overvalued, however, this can also depend upon the situation of the market; if the market is strong then it could suggest that Teva Pharmaceutical Industries Limited (TEVA) is a good investment, however if the market is weaker then it could suggest that the shares are undervalued. TEVA's value Change from Open was at 1.09% with a Gap of 0.22%. The firm's revenue was up 33.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.32 earnings per share. It tells us what percentage of revenue a company keeps after all its bills are paid.
Teva Pharmaceutical Industries Ltd (ADR) has a 52 week low of $31.90 and a 52 week high of $58.16 with a P/E ratio of 462.14 The company's market cap is now $0. Investors of record on Thursday, March 2nd were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 4.26%. Teva Pharmaceutical Industries's dividend payout ratio (DPR) is presently 1,657.38%.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and global copyright and trademark laws. TEVA's ROA is 0.41%, while industry's average is 10.79%.
Several hedge funds have recently modified their holdings of the stock. Rothschild Investment Corp IL boosted its position in Teva Pharmaceutical Industries by 1.5% in the third quarter. OLD Point Trust & Financial Services N A now owns 45,355 shares of the company's stock valued at $2,086,000 after buying an additional 150 shares during the last quarter. Bank of Montreal Can boosted its position in Teva Pharmaceutical Industries by 10.3% in the third quarter.
Teva Pharmaceutical Industries Limited (NYSE:TEVA), from Healthcare sector has been doing well recently. AGF Investments America Inc. now owns 22,947 shares of the company's stock valued at $1,056,000 after buying an additional 82 shares during the last quarter. Finally, OLD Point Trust & Financial Services N A increased its stake in Teva Pharmaceutical Industries by 0.3% in the third quarter. Macquarie Group Ltd. now owns 919,973 shares of the company's stock valued at $33,349,000 after buying an additional 29,770 shares during the last quarter. Cribstone Capital Management LLC now owns 3,241 shares of the company's stock valued at $144,000 after buying an additional 41 shares during the last quarter.
Norges Bank acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $495,909,000.
India beat Australia by 8 wickets to take series 2-1
On day one, debutant Kuldeep Yadav took 4-68 after Steve Smith (111) scored his 20th test hundred to take Australia to 300 runs. After losing the first Test match comprehensively, the Men in Blue came back strongly in the second Test .
China protests to India over Dalai Lama visit
China has criticized previous visits, but they did not spark any major rift between the two nuclear-armed Asian giants. Another issue that irked the Chinese was the huge voter turnout of the local people in the state elections.